Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05874843
Other study ID # 18124
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 11, 2023
Est. completion date July 30, 2024

Study information

Verified date May 2024
Source Indiana University
Contact Matthew Landman, MD, MPH
Phone 317-944-4681
Email landman@iu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Participants and their guardians will be asked to submit a small amount of blood at the beginning of an elective operation for analysis in the TEG 6s machine.


Description:

Trauma is the leading cause of death in children. Researchers, starting with Trunkey et al., have described three general time points of mortality after trauma - in the field, early secondary to hemorrhage and late due to infectious complications. Early mortality after trauma is specifically linked to hemorrhage. Trauma-induced coagulopathy is a multifactorial phenomenon present after trauma in both children and adults that can worsen hemorrhage and ultimately lead to increased mortality. Classical laboratory measurements of the coagulation pathway (PT, PTT, INR, fibrinogen, platelet count) have shown derangement after trauma and are correlated with mortality. However, these traditional tests of coagulation function take time to run as they are drawn and sent to a laboratory for evaluation and therefore provide a delayed snapshot of a potentially evolving coagulopathy scenario. Adult trauma centers have increasingly incorporated viscoelastic measures of the coagulation cascade to evaluate for and subsequently treat trauma-induced coagulopathy. One such test is thromboelastography (TEG) which is a whole blood assay that assesses functional clot kinetics and stability. It provides information on how various hemostatic factors, including coagulation factors, platelets, and fibrinogen, contribute to the clot. A 2016 randomized-controlled trial in adult trauma patients who met criteria for the institutions massive transfusion protocol were randomized to transfusion guided by TEG or by conventional measure of coagulopathy. The authors found increased survival in the TEG group as well as less transfusion of platelets and fresh frozen plasma. TEG assesses the clot rate, clot strength, and clot stability, which then assists the clinician in choosing appropriate blood component therapy. The American College of Surgeons Trauma Quality Improvement Program recommends the use of thromboelastography when patients are at risk for trauma-induced coagulopathy. Visicoeslastic evaluation of the coagulation pathway has become the standard of care in adult trauma patients to provide information on a patient's coagulation status, particularly when the patient is requiring multiple blood products. This allows the physician to deliver a targeted hemostatic resuscitation appropriate for the patient needs in real-time. This can result in a decrease of blood products and quicker reversal of the trauma induced coagulopathy. Riley Hospital for Children at IU Health has a TEG 5000 machine (Haemonetics Corp.) which performs the coagulation tests needed to help guide the resuscitation of a critical trauma patient. While an improvement over previous tests (such as INR, platelet count, PTT), the TEG 5000 still takes 45-60 minutes to get the results needed to guide fluid/blood resuscitation, making the results outdated as the patient has potentially received multiple units of blood products and/or had additional bleeding during that time. The TEG 5000 machine also has very specific environmental, and preparation needs (i.e. flat surface which is not bumped; controlled pipetting (dropping) of blood products into machine as well as mixing of reagents) that is very difficult to do in a busy trauma bay/emergency department with a critical patient. The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing. The sample is drawn automatically into the testing chambers rather than requiring manual pipetting, leading to less user variability. This simpler operation provides results in 15-20 minutes, making the test more clinically useful in guiding transfusion therapy during active bleeding. TEG 6s and TEG 5000 have been evaluated in adult patients with good agreement between the modalities. More specifically, the TEG 6s has been validated in adult trauma patients. However, few pediatric studies exist.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date July 30, 2024
Est. primary completion date July 30, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Months to 18 Years
Eligibility Inclusion Criteria: -Patients less than 18 years of age undergoing elective pediatric surgical care in the operating room at Riley Hospital for Children Exclusion Criteria: - Known disorder of coagulation pathway(s) - Administration of medications that may alter the coagulation cascade - Patients in foster care or wards of the court

Study Design


Intervention

Diagnostic Test:
Thromboelastography (TEG 6S)
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.

Locations

Country Name City State
United States Riley Hospital for Children Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary TEG 6s viscoelastic measurement, angle, in pediatric surgical patients To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges 2 months
Primary TEG 6s viscoelastic measurements, R time, in pediatric surgical patients To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges 2 months
Primary TEG 6s viscoelastic measurement, maximum amplitude, in pediatric surgical patients To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges 2 months
Primary TEG 6s viscoelastic measurement, lysis at 30 minutes, in pediatric surgical patients To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT01912547 - Thromboelastography During Surgery for Malignant Pleural Mesothelioma Phase 0
Completed NCT03674684 - ROTEM Assessment of Modern Crystalloid, Hydroxyethyl Starch and Gelatin Effect on Coagulation
Withdrawn NCT04705701 - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care N/A
Not yet recruiting NCT04515420 - The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Completed NCT04580563 - Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study N/A
Withdrawn NCT04274699 - Clinical Evaluation of the Hemosonics Quantra® Coagulation Monitor in Liver and Multivisceral Transplantation
Terminated NCT02540434 - Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions N/A
Completed NCT02203968 - Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST) Phase 1/Phase 2
Unknown status NCT01854476 - Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze Phase 2/Phase 3
Completed NCT00816127 - Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction N/A
Active, not recruiting NCT02926274 - Transfusion Using Stored Whole Blood N/A
Completed NCT05295693 - Quantra vs TEG for Congenital Cardiac Surgery - a Pilot Validation Study
Not yet recruiting NCT04582188 - The Early Coagulopathy for the Prognosis in Sepsis
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Recruiting NCT05449834 - Fibrinogen Early In Severe Trauma StudY II Phase 3
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Not yet recruiting NCT04115722 - Coagulation Parameters in IBD Patients
Completed NCT01228058 - A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients N/A
Active, not recruiting NCT04128488 - Effects of Gender-Affirming Hormone Therapy Among Transgender Women